Registration is complimentary and required to attend.
About this Webinar:
Laura Sepp-Lorenzino, PhD, CSO of Intellia Therapeutics presented the 2024 PODD Keynote on Cell & Gene Delivery of CRISPR-based gene editing medicines to achieve meaningful clinical impact. We are pleased to bring you this exclusive rebroadcast where Dr Sepp-Lorenzino specifically addresses:
- Intellia’s approach to develop therapeutics with customized modular delivery technology
- Updates on Intellia’s clinical programs including NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema
- Preclinical considerations for development of in vivo gene editing candidates
- An update on Intellia’s emerging in vivo and ex vivo pipelines
.
About PODD®, the webinar’s associated conference:
Partnership Opportunities in Drug Delivery (PODD®) is committed to upholding its tradition of combining partnering, access to cutting-edge business and scientific content in the field of drug delivery, with loyal support from a top notch speaking faculty. Pharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals and learn about a wide range of innovative drug delivery technologies that could improve the delivery of various types of drugs. This can include proteins, peptides, oligonucleotides, biologics, and small molecules and more. PODD provides business development opportunities through organized networking and a partnering tool for new, emerging and established collaborations.
Registration is complimentary and required to attend.
